Home > Rheumatology > EULAR 2020 > Rheumatoid Arthritis > Olokizumab significantly improves RA features and patient-reported outcomes

Olokizumab significantly improves RA features and patient-reported outcomes

Results from the phase 3 CREDO-1 trial show that treatment with olokizumab over a 24-week period was associated with significant improvements in the signs, symptoms, and physical function of rheumatoid arthritis (RA) as well as in patient-reported outcomes (PROs) in patients with moderate-to-severe RA who previously failed methotrexate therapy [1,2].

Prof. Rumen Stoilov (University Hospital St. Ivan Rilski, Bulgaria) presented the randomised, placebo-controlled, multicentre, phase 3 CREDO-1 trial that evaluated the efficacy and safety of olokizumab, a new humanised monoclonal antibody targeting interleukin(IL)-6 [3,4]. The trial aimed to evaluate the safety and efficacy of olokizumab 64 mg administered subcutaneously every 2 weeks and 64 mg subcutaneously every 4 weeks versus placebo in the treatment of moderate-to-severe active RA despite treatment with methotrexate. Participants (n=428) receiv...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on